Want to see SGMOQ full AI Analyst Report?
Top Page
Sangamo Therapeutics
(OTC:SGMOQ)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.05
▼(-80.77% Downside)
Action:Downgraded
Date:07/02/26
The score is driven primarily by very weak financial performance (declining revenue, large losses, heavy cash burn, and negative equity) and bearish technicals (price far below key moving averages with negative MACD). These risks are only partially offset by the earnings call’s positive regulatory progress for ST-920, while the bankruptcy/OTC transition further pressures the overall assessment.
Positive Factors
High gross margins
Sangamo reports very high gross margins (~74% TTM), reflecting low direct cost for its partnership/licensing revenue mix. Durable high margins mean incremental revenue can disproportionately improve operating leverage if commercial milestones or partner deals materialize, supporting future profitability once scale and revenue cadence stabilize.
Negative Factors
Heavy cash burn
Persistent negative operating and free cash flow (~-$90M TTM) indicates the company cannot self‑fund development and is structurally dependent on external financing or partner payments. Over months, this raises execution risk, increases likelihood of dilutive financings, and can delay or constrain R&D and regulatory milestones if capital access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sangamo reports very high gross margins (~74% TTM), reflecting low direct cost for its partnership/licensing revenue mix. Durable high margins mean incremental revenue can disproportionately improve operating leverage if commercial milestones or partner deals materialize, supporting future profitability once scale and revenue cadence stabilize.
Read all positive factors
Sangamo Therapeutics (SGMOQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.61M
Dividend YieldN/A
Average Volume (3M)7.65M
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-45.80%
EPS Growth-0.16%
CountryUS
Employees183
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding414,288,850
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market Cap2.78
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$2.00Price Target Upside669.23% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$9.90M
Sangamo Therapeutics Business Overview & Revenue Model
Company Description
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, gen...
How the Company Makes Money
Sangamo Therapeutics primarily generates revenue through collaboration and licensing arrangements rather than product sales, as product revenue is null (no commercial products). Under these partnerships, Sangamo can earn (1) upfront payments when ...
Sangamo Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.56M | 39.55M | 57.80M | 176.23M | 111.30M | 110.70M |
| Gross Profit | 34.56M | 31.95M | 57.80M | 176.23M | 99.19M | 110.70M |
| EBITDA | -117.46M | -115.90M | -89.09M | -96.80M | -179.74M | -160.35M |
| Net Income | -123.33M | -122.93M | -97.94M | -257.83M | -192.28M | -178.29M |
Balance Sheet | ||||||
| Total Assets | 59.97M | 59.74M | 101.64M | 165.32M | 562.51M | 721.92M |
| Cash, Cash Equivalents and Short-Term Investments | 27.59M | 20.95M | 41.92M | 81.00M | 277.63M | 376.55M |
| Total Debt | 19.33M | 26.80M | 30.57M | 38.10M | 43.11M | 48.08M |
| Total Liabilities | 78.92M | 74.01M | 78.86M | 82.43M | 267.55M | 346.58M |
| Stockholders Equity | -18.95M | -14.27M | 22.77M | 82.89M | 294.96M | 375.34M |
Cash Flow | ||||||
| Free Cash Flow | -90.46M | -97.31M | -67.41M | -246.00M | -243.80M | -256.53M |
| Operating Cash Flow | -90.34M | -97.21M | -67.14M | -224.84M | -223.63M | -233.25M |
| Investing Cash Flow | -115.00K | -102.00K | 37.52M | 153.53M | 59.28M | 248.20M |
| Financing Cash Flow | 89.31M | 70.75M | 28.38M | 14.59M | 84.66M | 32.86M |
Sangamo Therapeutics Technical Analysis
Negative
0.26
Price Trends
0.15
Negative
0.25
Negative
0.38
Negative
Market Momentum
-0.04
Positive
32.58
Neutral
14.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMOQ, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.15, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 32.58 is Neutral, neither overbought nor oversold. The STOCH value of 14.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMOQ.
Sangamo Therapeutics Risk Analysis
Sangamo Therapeutics disclosed 62 risk factors in its most recent earnings report. Sangamo Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sangamo Therapeutics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $174.56M | -1.24 | -100.13% | ― | 12.96% | 12.51% | |
46 Neutral | $105.44M | -2.42 | -36.37% | ― | -100.00% | -1056.82% | |
45 Neutral | $98.10M | -2.18 | -2748.16% | ― | ― | 43.68% | |
43 Neutral | $487.53M | -1.52 | -131.58% | ― | ― | 22.16% | |
40 Underperform | $23.61M | -0.20 | 6686.36% | ― | -45.80% | -0.16% |
* General Sector Average
SGMOQ
Sangamo Therapeutics
0.06
-0.48
-89.35%
CABA
Cabaletta Bio
2.99
1.39
86.88%
BDTX
Black Diamond Therapeutics
1.84
-0.76
-29.23%
ELTX
Elicio Therapeutics
5.14
-2.71
-34.52%
CRBU
Caribou Biosciences
1.76
0.39
28.47%
Sangamo Therapeutics Corporate Events
Delistings and Listing ChangesLegal Proceedings
Sangamo Shares Shift to OTC Market Amid Bankruptcy
Negative
Jul 1, 2026
On June 24, 2026, Sangamo Therapeutics’ common stock began trading on the OTCID Basic Market under the symbol SGMOQ, reflecting the company’s transition into over-the-counter trading after its voluntary Chapter 11 bankruptcy filing. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.